HopeStage
Back to all studies
CompletedNCT00237809

D-serine for cognitive symptoms of schizophrenia

About this titleRead the official source — NCT00237809
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
New Haven and 1 more locationSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2002
Recruitment status
Completed
Enrollment listed in the registry
104
Sponsor
Yale University
Sponsor type
University
Study type
Behavioral
Intervention type
Behavioural, Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00237809
Official title
Show the full official title

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven · West Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Did this study involve medication?

Yes. The study involved medication, including D-serine and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies